Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ME Therapeutics HoldingMETXF 14 EBITDA Margin % is 0.00% as of May. 2026. GuruFocus rates METXF with a GF Score™ of 14/100. The stock has 1 warning sign investors should review. Among 940 Biotechnology companies, ME Therapeutics Holding ranks worse than 106382.87% on this metric.
ME Therapeutics Holding (OTCPK:METXF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
ME Therapeutics Holding EBITDA Margin % Related Terms
ME Therapeutics Holding EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
METXF vs VRTX, REGN, RVMD: EBITDA Margin % Comparison
For the Biotechnology subindustry, ME Therapeutics Holding's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ME Therapeutics Holding EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ME Therapeutics Holding's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where ME Therapeutics Holding's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ME Therapeutics Holding (METXF) has a EBITDA Margin % of 0.00% as of May. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on ME Therapeutics Holding and its competitors. According to the industry distribution chart, ME Therapeutics Holding ranks #999999 out of 940 companies in the Biotechnology industry.
Is ME Therapeutics Holding's EBITDA Margin % too high?
ME Therapeutics Holding's current EBITDA Margin % is 0.00%. Based on the distribution chart, ME Therapeutics Holding ranks #999999 out of 940 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ME Therapeutics Holding has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does ME Therapeutics Holding's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ME Therapeutics Holding ranks #999999 out of 940 companies for EBITDA Margin %. This places ME Therapeutics Holding in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on ME Therapeutics Holding and its competitors. ME Therapeutics Holding's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ME Therapeutics Holding stock overvalued right now?
ME Therapeutics Holding (METXF) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. ME Therapeutics Holding's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For ME Therapeutics Holding (METXF), the current EBITDA Margin % is 0.00% as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ME Therapeutics Holding Inc is a preclinical stage biotechnology company working on cancer-fighting drugs in the field of Immuno Oncology, developing next-generation therapeutics targeting immune suppression in cancer. It is developing novel drugs that target myeloid cells to directly treat cancer and enhance the benefits of current Immuno Oncology drugs, such as checkpoint inhibitors in currently untreatable cancers. Immuno Oncology is a new area of cancer research that has been successful in treating previously untreatable cancers by targeting the immune system rather than the cancer directly, allowing a single drug to be used for multiple cancer types with mostly manageable side effects.
14GF Score
Get the complete analysis for METXF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
METXF has been successfully added to your 
